# BIO 2017 – San Diego WORKING WITH THE MEDIA

... Thoughts for Bioentrepreneurs

Moira Gunn, Ph.D.

Host, BioTech Nation, Tech Nation Health & Tech Nation
National Public Radio 24-Hour Program Stream
NPR Channel/SiriusXM, NPR Worldspace

Director, Business of Biotechnology Program

School of Management, University of San Francisco



Business of Biotechnology Program



BIO 2017 Biotechnology Entrepreneurship Boot Camp

Welcome to the your

Biobusiness Media Primer !!!





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### A few questions:

Anyone here a member of the media?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### A few questions:

- Anyone here a member of the media?
- Anyone a <u>former</u> member of the media?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### A few questions:

- Anyone here a member of the media?
- Anyone a <u>former</u> member of the media?
- Experience dealing with the media?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### A few more questions:

Anyone here been <u>misrepresented</u> in the media?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### A few more questions:

- Anyone here been misrepresented in the media?
- Anyone here with <u>a positive experience</u> with the media?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

You've just participated in ...

# **LESSON #1**





BIO 2017 Biotechnology Entrepreneurship Boot Camp

You've just participated in ...

# LESSON #1 Know Your Audience





BIO 2017 Biotechnology Entrepreneurship Boot Camp

# When you are targeting journalists and media outlets ...

# Know their Audience





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Now you are ready for ...

### **LESSON #2**





BIO 2017 Biotechnology Entrepreneurship Boot Camp

LESSON #2 You Cannot Control What the Media Reports about You ... But You Can Give Yourself Your Best Shot



Business of Biotechnology Program



BIO 2017 Biotechnology Entrepreneurship Boot Camp

### Caveat ...

What I'm telling you is

<u>my experience</u>

being a member of

the Global Science-Business Media





#### BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### **JOURNALIST**

- Host, Tech Nation and its segment, <u>BioTech Nation</u> and a \*new\* segment <u>Tech Nation Health</u> on NPR
- Author, "Welcome to BioTech Nation"
- Multiple domestic stations, airplays on NPR 24-hour program stream, NPR Sirius-XM (full nationwide + global coverage), NPR WorldSpace, AFRTS to 177 countries, et al.
- Podcasts, iTunes, Stitcher, et al.
- In the biotech field, 900++ interviews with CEOs, VCs, policymakers, elected officials, regulators, etc.
- At each BIO, 45-60 interviews









#### BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### **PROFESSOR**

- School of Management,University of San Francisco
- Director, Business of Biotechnology Program
- Cross-university graduate program
- Serves MBA/JD-MBA/ Masters Info Systems/ Professional Sci Masters, Biotech, and others
- 400+ graduate students to date

#### **Exemplar Courses**

- Local, National & Global Bio-Business
- The Information of Biotech
- Legal, Social & Ethical Implications of Biotech
- Study Tours to Global Bioclusters London/Oxford/Cambridge,
   Switzerland, Wash, DC, Puerto Rico, Australia, Canada, San Diego





BIO 2017 Biotechnology Entrepreneurship Boot Camp

The *journalist* in me wants to tell you **HOW** to deal with the media ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

The *journalist* in me wants to tell you **HOW** to deal with the media ...

The *professor* in me wants to tell you **WHY** 





BIO 2017 Biotechnology Entrepreneurship Boot Camp

So let's start there ...

# Why should a Biotech Business be concerned about Media?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Because ...

Media drives Perception





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Because ...

Media drives Perception

Media drives Google-able Data





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Because ...

Media drives Perception

Media drives Google-able Data

Media does \*NOT\* drive Truth





BIO 2017 Biotechnology Entrepreneurship Boot Camp

And ...

# Perception drives What You Can Do





BIO 2017 Biotechnology Entrepreneurship Boot Camp

What's the difference between <u>Advertising</u> and <u>Public Relations</u>?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

What's the difference between <u>Advertising</u> and Public Relations?

In Advertising, **you** say you're great





BIO 2017 Biotechnology Entrepreneurship Boot Camp

What's the difference between <u>Advertising</u> and <u>Public Relations</u>?

In Advertising, **you** say you're great
In Public Relations, **somebody else** says you
are great





BIO 2017 Biotechnology Entrepreneurship Boot Camp

What's the difference between <u>Advertising</u> and <u>Public Relations</u>?

In Advertising, <u>you</u> say you're great
In Public Relations, <u>somebody else</u> says you
are great ... or <u>not</u>





BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### WHAT DO YOU NEED TO DO?

#### WHERE DOES MEDIA FIT ...

... in the transition from <u>cutting-edge science</u> to the <u>registered product</u>???





BIO 2017 Biotechnology Entrepreneurship Boot Camp

You need it when you are raising money ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

You need it when you are raising money ... you need it when you are raising money ... you need it when you are raising money ... you need it when you are raising money ... you need it when you are raising money ... you need it when you are raising money ... you need it when you are raising money ... you need it when you are

raising money ... you are raising







#### **WORKING WITH MEDIA**

#### **Traditional Target Audiences**

#### Biobusiness Media Audiences

Venture Capitalists
Industry Analysts
Regulatory Personnel
Biotech Industry Organizations
Service Professionals
Financial Advisors
Policymakers
Legislators
Insurance Providers

Healthcare Providers

- Hospitals
- Healthcare Systems
- Individual Providers
   Industry Organizations
   Educators
   Special Interest Groups
   Consumer Advocates
   Consumers





BIO 2017 Biotechnology Entrepreneurship Boot Camp

A Frequent Source of Money ...

**Venture Capitalists** 





BIO 2017 Biotechnology Entrepreneurship Boot Camp

A Frequent Source of Money ...

**Venture Capitalists** 

Back to Lesson #1 – Know Your Audience

Who are they?
What is important to them?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Here's some insight into who the VC's are in the **Biopharma** space ...

- Sought to validate the Bioenterprise Innovation Expertise Model (BIEM 2.0) through experienced biopharma VC's
- > An ancillary result was insight into the VC's





# Journal of Commercial Biotechnology (2016) 22(2) 50-63

#### Article

## The BIEM Verification Study: Experienced Venture Capitalists Assess a Biopharmaceuticals Innovation Expertise Model

#### Moira Gunn

founded and directs the Business of Biotechnology Program in the School of Management at the University of San Francisco, where she is an assistant professor. The former President of SIBER, the Society for International Bioentrepreneurship Education and Research, she also hosts Tech Nation, and its regular segment BioTech Nation, which air on the NPR channel of SiriusXM, among other venues.

#### Nola Masterson

is Founder and Managing Director of Science Futures Management Company, LLC, and an Adjunct Professor in the Business of Biotechnology Program in School of Management of University of San Francisco.

#### Paul Lorton, Jr.

is a Professor of Management Information Systems in the School of Management at the University of San Francisco.

#### **Jacques Baronet**

is a Professor of Entrepreneurship and Innovation Management at the University of Sherbrooke, Quebec, Canada.

#### ABSTRACT

Developing biopharmaceutical therapies is a scientifically complex endeavor, requiring from ten to fifteen years of effort with successive rounds of increasingly greater investment capital in a risk-intensive landscape. With failure rates at 88%, and an all-attempts-averaged investment of over \$2B per approved drug, discussions of what leads to success and/or failure are pervasive. In this milieu, the BIEM (Bioenterprise Innovation Expertise Model) model was developed so that the status of a bioenterprise could quickly be assessed. Assessing the BIEM model, 20 biopharmaceuticals venture capitalists with 30 years average biotechnology industry experience, all having board experience, most having served as board chairs, and 80% having been CEO's and/or presidents, rated the innovation expertise disciplines of BIEM 2.0 as to their importance in the scientific discovery through market-ready product innovation phase of biopharmaceutical development. Despite a small sample size, statistically significant insights were produced, verifying the BIEM model. The most important innovation expertise disciplines were intellectual property, science, regulatory expertise, and venture capital, in that order. Further, the strongest correlations linked regulatory expertise and science, and equally so, intellectual property and venture capital. Additional insights with respect to the profiles of the biopharmaceutical venture capitalists themselves is also presented.



#### **Bioenterprise Innovation Expertise Model (BIEM 2.0)**







## Validating BIEM 2.0


BIO 2017 Biotechnology Entrepreneurship Boot Camp

- 20 Biopharmaceutical VCs
  - Minimum biobusiness expertise: 20 years
  - Average biobusiness expertise: 30 years
- Validated all the BIEM disciplines
  - □ Introduced/suggested no add't'l disciplines
- Interrelations Most Strongly Correlated
  - □ IP with Venture Capital
  - Regulatory Expertise with Science
  - Technology with Information Systems






### Experienced Biopharmaœuticals Venture Capitalists' Assessment of BIEM Model Innovation Expertise



### Who are the Biopharma VC's?


BIO 2017 Biotechnology Entrepreneurship Boot Camp

Experienced Biopharmaceuticals Venture Capitalists' Biotechnology Industry Career Positions Held



### **How do VC's Rate Their Own Expertise?**

#### Self-Assessed Combined Primary and Secondary Expertise Profiles Biopharmaceuticals Venture Capitalists



### Validating BIEM 2.0

BIO 2017 Biotechnology Entrepreneurship Boot Camp

- No New expertise areas were identified
- Not All expertise areas important at every stage
- Expertise <u>dynamically</u> needed over time
  - Every organization/effort is <u>unique</u>
- Every bioenterprise could need Media Savvy at any stage of development from inception through to fully-delivered product





### Validating BIEM 2.0

BIO 2017 Biotechnology Entrepreneurship Boot Camp You get a meeting with a VC ...

### They will google you immediately beforehand

... you better google you beforehand

### Do you have an answer for everything?

... at least you should know about the item

### How do you play "DEFENSE" when it's serious?

... here's how





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Case Study #1: Playing Defense

Date: 2015

The Biotech Marketspace: Oncolytic Viruses

Media Outlet: Breaking Industry News





BIO 2017 Biotechnology Entrepreneurship Boot Camp

# **Amgen**

Profile: Large biopharma firm, Thousand Oaks, California
Trades on NASDAQ at roughly \$164/share

2015 Revenue: \$22 Billion

Back in 2015, has a Lead Oncolytic Virus product candidate:

>>> "T-Vec" for Melanoma

>>> No others approved at the time





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Sample Media Outlet: "Fierce Biotech" – fiercebiotech.com

**DDF 2017** 

FiercePharma

lohs

Resources

ents Subscribe









BIOTECH

RESEARCH

CRO

MEDTECH



### BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### **FierceBiotech**

#### A publication of Fierce Markets

FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!

#### The FierceMarkets Network:

#### Telecom

FierceCable FierceDeveloper FierceWireless:Europe FierceWirelessTech FierceOnlineVideo FierceTelecom FierceWireless FierceInstaller

#### Marketing & Retail

FierceCMO FierceMobileMarketer FierceRetail FierceRetaillT FierceMobileRetail

#### Healthcare

FierceEMR FierceHealthcare FierceHealthFinance FierceHealthIT FierceHealthPayer FierceHealthPayerAntiFraud FierceMobileHealthcare FiercePracticeManagement Hospital Impact

#### Government

FierceGovernment FierceGovernmentIT FierceHomeland Security FierceMobileGovernment FierceCities FierceGovHealthIT

#### Life Sciences

FierceAnimalHealth

FierceBiotechResearch FierceBiotech FierceBiotechIT FierceCRO FierceDiagnostics FierceDrugDelivery FierceMedicalDevices FiercePharma FiercePharmaAsia FiercePharmaManufacturing FiercePharmaMarketing FierceVaccines 4 1

#### Enterprise IT

FierceBigData FierceCIO FierceContentManagement FierceDevOps FierceEnterpriseCommunicatio FiercelT Security FierceMobileIT Energy

FierceEnergy SmartGridNews

#### Finance

FierceCFO FierceFinancelT





## Back in June, 2015 ...

### Fierce Vaccines

NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE











### Hold the offer: Bavarian Nordic declares it's not for sale

Despite the M&A wave across biopharma that doesn't show signs of slowing, Bavarian Nordic's top dog has said his company isn't interested in getting involved.

#### Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken



#### TOP HEADLINES

#### EDITOR'S CORNER -

#### Globelmmune's Gileadpartnered hep B vaccine fails in Phase II

Globelmmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences. Read more from FierceBiotech >>

#### Serum Institute, Cipla partner to market flu vaccine in India

May 28, 2015

Serum Institute of India and compatriot Cipla have inked a pact to market a flu vaccine.

#### Amgen publishes pivotal T-Vec data as it awaits FDA decision

May 28, 2015

Riding momentum from an FDA

# SIGN UP FOR OUR NEWSLETTER

**EMAIL ADDRESS** 

SIGN ME UP

Fierce Vaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join 25,000+ lab research professionals who get Fierce Vaccines via weekly email. Sign up today!



THE LIBRARY: WEBINAR



#### Hold the offer: Bay declares it's not fo

Despite the M&A wave across bis show signs of slowing, Bavarian said his company isn't interested

Takeda, Daiichi Sanky distribution pacts with Kaketsuken

### Amgen publishes pivotal T-Vec data as it awaits FDA decision

May 28, 2015

Riding momentum from an FDA advisory committee recommendation last month, Amgen rolled out its data from a pivotal study of its cancer vaccine talimogene laherparepvec (T-Vec) on Tuesday as it awaits the agency's final decision, expected later this year.



Riding momentum from an FDA

THE LIBRARY: WEBINAR



Business of Biotechnology Program







BIO 2017 Biotechnology Entrepreneurship Boot Camp

Typical media scenario ...

Make a press announcement when FDA <u>panel</u> makes a positive decision

Make another press announcement with **final** FDA decision

### What's this item about?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

So I entered "T-Vec" in the Search Box ...





### Results of "T-Vec" search in FierceBiotech ...

#### Amgen publishes pivotal T-Vec data as it awaits FDA decision

Fierce Vaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

# UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But **T-Vec** ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

It meant that prior to this new Amgen story, if anyone entered "T-Vec" in the Search Box, the **first thing** to pop up would be ...

# UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

It meant that prior to this new Amgen story, if anyone entered "T-Vec" in the Search Box, the **first thing** to pop up would be ...

### UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

... this is not good ... and it has nothing to do with T-Vec





#### Amgen publishes pivotal T-Vec data as it awaits FDA decision

Fierce Vaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

### UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

# Might Amgen have strategically pushed the "Suicide stunner" headline down by intentionally creating a new story?





#### Amgen publishes pivotal T-Vec data as it awaits FDA decision

→ Fierce Vaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

### UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...

#### Consistent

Positive/

**Non-problematic** 

**Mentions** 

In FierceBiotech

#### NewLink continues cancer vaccine Ph III trial with interim data under wraps

FierceVaccines | May 14, 2015.

with Bristol-Myers Squibb's (\$BMY) Yervoy, and Amgen (\$AMGN), which is testing its T-Vec with Merck's ...

### Profound reverse-merges onto TSX; Startup wins €2M to develop novel dialysis tech;

FlerceMedicalDevices (May 1, 2018)

@JohnCFierce: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes ...

#### Omnicare draws buyout interest from Express Scripts, CVS; Akorn asks Oklahoma not to use its drugs to execute;

FlercePharms | May 1, 2015

next big M&A splash. Articles | Follow @FierceBiotech @JohnCFierce: T-Vec panel demonstrates just ...

#### Amgen wins FDA panel n An EEG via a tattoo?; Samsung testing Alzheimer's memory app;

Fierce Vaccines | April 29, 2015

PerceMedicalDevices | April 30, 2015

wins FDA panel nod for T-Vec in melanoma. News > Final trial results show GSK malaria vaccine's ...

#### submits melanoma-fighter T-Vec

#### Report: Pfizer bids on Sobi; Bellicum buys into TCR;

April 30, 2015

than Merck's Zostavax in older adults, study says. Story > Amgen wins FDA panel nod for T-Vec ...



Business C Celgene sales miss, profits double; Opdivo closes in on first-line melanoma Biotechnolc use;

Program - ReicePhaima | April 30, 2015

Merck's Zostavax in older adults, study says. Story > Amgen wins FDA panel nod for T-Vec in melanoma.



### By the next day, the headlines were already moving again ...

#### UPDATED: Bristol-Myers dominates--and disappoints--at ASCO immunooncology debut

May 29, 2015

Laboratories. Related Articles: FDA panel gives a thumbs up to Amgen's T-Vec for melanoma Bristol-Myers ...

#### Amgen publishes pivotal T-Vec data as it awaits FDA decision

→ Fierce Vaccines | May 28, 2015

Despite meeting the primary endpoint in the trial, T-Vec fell short of its secondary endpoint of overall ...

# UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

May 23, 2015

drug T-Vec, while Corlanor (ivabradine) was approved as a new heart therapy in April. But T-Vec ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

**LESSON #156** 

If there is inadvertent
"negative perception",
create a new (and different!)
story to push it down





BIO 2017 Biotechnology Entrepreneurship Boot Camp

**LESSON #182** 

Even on "Offense", You still need

A good story

Your \*own\* good story





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Case Study #2: Let's Play Some More Defense

HONG KONG

**PUERTO RICO** 





BIO 2017 Biotechnology Entrepreneurship Boot Camp

# The Tyranny of

### **INDUSTRY REPORTS**





BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### **HONG KONG**

Profile: Life Science Industry – Pharmaceuticals, Traditional Chinese Medicines, Medical Devices and Biotechnology

250-300 biotech-related companies70 listed on Hong Kong Stock Exchange

"The total number of basic medical publications per year was doubled to about <u>700</u> between 1997 – 2002. It is estimated that Hong Kong universities produce about <u>250</u> biomedical publications of high impact factor per annum at present." Hong Kong Innovation and Technology Commission, April 12, 2017





BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### **Puerto Rico**

**Profile: Life Science Industry – Pharmaceuticals,** 

**Medical Devices and Biotechnology** 

Pharmaceuticals - \$40B/year

7 of top 10 drugs manufactured there

12 of top 20 pharma/biopharma companies there

49 FDA-approved manufacturing plants

**Medical Devices - \$4B/year** 

7 of top 10 drugs manufactured there

12 of top 20 medical device companies there

78 medical device manufacturing plants



Business of Biotechnology Program





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### **Hong Kong & Puerto Rico**

<u>Neither</u> are Nation-States per the United Nations

PR – U.S. Territory

HK – Autonomous Territory of China

### But what does this matter?





BIO 2017 Biotechnology Entrepreneurship Boot Camp

# Let's look at **INDUSTRY REPORTS**





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### Scientific American WorldVIEW +++ ScoreCard


www.saworldview.com





Download the latest issue of Scientific American Worldview »

WORLDVIEW 100 - SCIENCE OF COMMUNICATION - SCORECARD - BENCH TO BUSINESS - COUNTRY SPOTLIGHTS - SPONSORS - ABOUT US - ARCHIVE





### WORKI

BIO 2017 Biotechnology E

2015 Scientific American WorldVIEW Scorecard

"Author! Author! The highest ranked nations publish the most"



#### AUTHOR! AUTHOR!


The highest-ranked nations publish the most

As a meta-analysis, the Scientific American Worldwiew Scorecard is created from a broad collection of data comparisons. This year we added a new resource to this mix, the Nature Index [http://www.natureIndex.com/]\_which tracks scientific publications. In past issues we've examined the connection between a nation's rank on the Scorecard and its publishing output, and the index allows us to revisit that concept—but with data from a fair greater number of countries. Our results show that sayeral nations in particular generate many more publications than might be expected.

The Nature Index not only provides a database of scientific publications but it also keeps track of the institutional and country affiliations of each author, it divides articles in four main categories: chemistry, earth and environmental sciences, life sciences and physical sciences. Data for each country are collected by article count (AC), with each mation receiving a credit for any article in which it can claim one of the authors. The database also calculates aweighted tractional count WFCL which indicates the percentage of authorship from a country (and includes an adjustment that addresses an imbalance in some of the journals being tracked).

For each country, we compare the Nature index 2014 WFC for life sciences articles to the overall Scorecard ranking (excluding Hong Kong and Puerto Rico, which are not in the Nature index). Not curprisingly, the results show considerable scatter, especially since some coame nts of the life sciences do not relate to biotechnology. Likewise, other categories of the Nature Index, such as the mistry, include articles that would impact aspects of biotechnology. Nonetheless, the graph shows that a hilgher overall Scorecard finish is associated with a higher article output. In fact, the findings suggest a potentially exponential correlation.

Certain countries score much higher than expected. For example, the U.S. WFC lands nearly off the chart--- more than four times greater than predicted by the correlation equaexpectations, publishing fair more articles than other nations finishing as low as it does on the publishing lots of articles is not the same as publishing lots of valuable articles.



### WORKI

BIO 2017 Biotechnology E

2015
Scientific American
WorldVIEW Scorecard

#### AUTHOR! AUTHOR!

The highest-ranked nations publish the most

As a meta-analysis, the Scientific American Worldwise Scorecard is create 6 from a broad collection of data comparisons. This year we added a new resource to this mbr, the Nature index (http://www.naturelindex.com/j., which tracks scientific publications. In past lesses we've examined the connection between a nation's rank on the Scorecard and its publishing output, and the Index allows us to revisit that concept—but with data from a far greater number of countries. Our results show that several nations in particular generate many more publications than might be expected.

The Nature Index not only provides a database of scientific publications but it also keeps track of the Institutional and country affiliations of each author, it divides articles in four main categories: chemistry, earth and environmental sciences, the sciences and physical sciences. Data for each country are collected by article count [AC], with each nation receiving a credit tractional count [WFC], which indicates the percentage of authorship from a country (and includes an adjustment that addresses an imbalance in some of the journals being tracked).


For each country, we compare the Nature Index 2014 WFC for life sciences articles to the overall Scorecard ranking (excluding Heng Kong and Puerto Rico, which are not in the Nature Index). Not curprisingly, the results show considerable scatter, especially since some segments of the life sciences do not retate to biotechnology. Likowise, other categories of the Nature Index, such as chemistry, include articles that would impact aspects of biotechnology. Nonetheless, the graph shows that a ligher overall Scorecard finish is associated with a higher article output. In fact, the findings suggest a potentially exponential correlation.

Certain countries score much higher than expected. For example, the U.S. WFC lands nearly off the chart—more than four times



"For each country, we compare the Nature Index 2014 WFC for life sciences articles to the overall Scorecard ranking (excluding Hong Kong and Puerto Rico, which are not in the Nature Index.)"





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Let's look in the NATURE Index ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

Let's look in the NATURE Index ...

"404 Page not found"





BIO 2017 Biotechnology Entrepreneurship Boot Camp

# PUERTO RICO ... is not a country HONG KONG ... is not a country

 But its universities and research institutions – and their publications – are separately listed in the Nature Index

If you scrape that data, the picture changes







BIO 2017 Biotechnology Entrepreneurship Boot Camp

### **Puerto Rico & Hong Kong**

Inadvertently marginalized and misrepresented in these two respected industry reports

Also, Puerto Rico has <u>mainstream</u> media problems

#1 – \$76 Billion in debt

#2 – The Zika virus

#3 - ... and ...





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### Puerto Rico – John Oliver, Lin Manuel Miranda



BIO 2014 Bio-Entrepreneurship Boot Camp

No matter what, the **POINT** of **Media Savvy** is to ...

#### **REACH ESSENTIAL TARGET AUDIENCES**





#### BIO 2017? – Can get pre-registered Media Lists

									1
24	Alex	Keown	Freelance Journalist	BioSpace	IA		1 8177	keown.a	Yes
25	Harry	Tracy	Editor and Publisher	NeuroPerspective	CA		1 7607	neuro@r	Yes
26	Jennifer	Boggs	Managing Editor	BioWorld Today	GA		1 7708	jennifer.	. Yes
27	Ken	Stone	Contributing editor	Times of San Diego	CA		1 6192	kens@tii	Yes
28	Lisa	Lamotta	Editor	Informa Life Sciences Group	DC		1 9085	llamotta	Yes
29	Beth	Kutscher	Healthcare news editor	Modern Healthcare	CA		1 4158	bkutsche	Yes
30	Ron	Leuty	Biotech reporter	San Francisco Business Times	CA		1 4152	rleuty@l	Yes
31	Katelyn	Busse	Scientist	Biotech Weekly	CA		1 6092	katelyn@	Yes
32	Johann	Tsai	Journalist	Global Bio & Investment Monthly		Taiwan	8862 2	johann.t	Yes
33	Karen	Pihl-Carey	Analyst	BioWorld Today	PA		1 7708	karen.pil	Yes
34	Joshua	Berlin	Executive Editor	BioCentury Inc.	CA		1 6505	jberlin@	Yes
35	Donald	Zuhn	Editor	Patent Docs	IL		1 3129	zuhn@m	Yes
36	Owen	Hughes	Senior Editor	UC Technology Journal	CA		1 5307	uctechjo	Yes
37	Marie	Powers	News Editor	BioWorld Today	GA		1 7704	marie.pc	Yes
38	Laura	Helbling	Senior Writer	The Pink Sheet/Informa	DC		1 5738	laura.hel	Yes
39	Wayne	Koberstein	Executive Editor	Life Science Leader	OR		1 5415	wayne.k	Yes
40	Tamra	Sami	International business journa	Pharmasia News	Western A	Australia	61 04 5	T.Sami@	Yes
41	Karen	Jagoda	Host and Producer	Empowered Patient Podcast	CA		1 8586	kjagoda(	Yes
42	Kim	Walpole	Producer	Empowered Patient Podcast	CA		1 5184	kim@tria	Yes
43	Anne	Montgomery	Editor in Chief	BioProcess International	OR		1 5416	amontgo	Yes
44	Jim	Miller	Editor	Advanstar Communications, Inc	VA		1 7033	jim.mille	Yes
45	James	Cavuoto	Editor	Neurotech Business Report	CA		1 4155	editorial	Yes
46	Lisa	Melton	Senior News Editor	Nature Biotechnology		United Kir	44 20 7	l.melton	Yes

UNIVERSITY OF SAN FRANCISCO Biotechnology Program







#### **Best Way to reach Traditional Journalists:**

## **One-on-One Relationships**

... but you still need press releases and marketing materials





#### So people hire a public relations professional:

Good Idea!





#### So people hire a public relations professional:

- Good Idea!
- Hire one who has good relationships with media





#### So people hire a public relations professional:

- Good Idea!
- Hire one who has good relationships with media
- But when they connect you, YOU need to cultivate the relationship with media





#### So people hire a public relations professional:

This is YOUR relationship with professional journalists





#### So people hire a public relations professional:

- This is YOUR relationship with professional journalists
- Do NOT hire the PR person to have the relationship FOR YOU





#### So people hire a public relations professional:

- This is YOUR relationship with professional journalists
- Do NOT hire the PR person to have the relationship FOR YOU
- Say goodbye to any PR person who isn't trying to get you in front of journalists





#### One more kicker ...

- Professional business journalists preferred source of reliable – and quoted – information is ... the <u>CEO</u>
  - Highest ranking of preferred sources: 36% (Messner, et al)





#### Other ways to get in front of journalists

- Work with industry organizations
  - BIO and its regional counterparts leap to mind
  - Industry organizations cultivate journalist contacts on your behalf
- Work with press offices at professional conferences you attend – anyone know where the pressroom is here at BIO?





Now let's talk about Social Media ...





Now let's talk about Social Media ...

## **Direct to Target Audience**





BIO 2017 Biotechnology Entrepreneurship Boot Camp

## Target Audiences

can be reached BY PROXY through

### TRADITIONAL MEDIA

can be reached **DIRECTLY** through

### SOCIAL MEDIA





In addition to interacting with social media, the bio-enterprise can ITSELF use Social Media *proactively* to *influence communities* ...

Genomic Health's -Facebook/YouTube/Twitter campaign:

"Pass It On ... Until Every Woman Knows"





## Independent of Type of Media ...





### First Challenge

You need to describe both the Business Proposition <u>AND</u> Science





### Second Challenge

#### ETHICAL PERSUASION

# Getting Accurate and Persuasive INFORMATION OUT, While Correcting MISINFORMATION





## Rules for Journalists

#### **Know Your Journalist**





## Rules for Journalists

## What's everybody's favorite subject? Themselves \*\*

\*\* True also for journalists ...





## Rules for Journalists

# What's everybody's 2<sup>nd</sup> favorite subject?

... Humans





## Rules for Journalists

## Every Journalist needs a <u>different</u> story





## Rules for Journalists

## Constantly <u>re-vitalize</u> your story/stories





### "KALEIDOSCOPE" YOUR STORIES









## Rules for Journalists

## Come back next time with a NEW story





## Rules for Journalists

#### Tell the Truth \*\*

\*\* (Tell your Truth)





**Table 5:** The TARES Test: Five principles of ethical persuasion<sup>26</sup>

Truthfulness (of the message)

Authenticity (of the persuader)

Respect (for the persuadee)

Equity (of the personal appeal)

Social Responsibility (for the common good)





## Rules for Journalists

## Have people that journalists can talk to ... \*\*

\*\* CEO, scientists, ...





## Rules for Journalists

Be open about the competition
Be respectful about the competition
Be accurate about the competition





## Rules for Journalists

## <u>Listen</u> to what the journalist tells you he or she is interested in





## Rules for Journalists

## Never ask the journalist to do any work





## Rules for Journalists

## <u>Always</u> return the journalist's <u>call</u>





## Rules for Journalists

## Even if you have <u>nothing to say</u>





## Rules for Journalists

## Especially if you have nothing to say





## Rules for Journalists

## You can <u>never control</u> the story





## Last Rule for Journalists

## It's not just who you know ... It's who, who you know, knows





BIO 2017 Biotechnology Entrepreneurship Boot Camp

#### Thank You!!!





BIO 2017 Biotechnology Entrepreneurship Boot Camp

### QUESTIONS ...





... Thoughts for Bio-Entrepreneurs

Moira Gunn, Ph.D.

Host, BioTech Nation & Tech Nation

National Public Radio 24-Hour Program Stream

Director, Business of Biotechnology Program

School of Management, University of San Francisco



Business of Biotechnology Program

